Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) recurrence after liver transplantation occurs in approximately 20% of patients. Most of these patients use immunosuppressant drugs. Meanwhile, patients with HCC recurrence are frequently treated with the small molecule kinase inhibitor (SMKI) sorafenib. However, sorafe...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/1/46 |